Described herein are biomaterials, systems, and methods for guiding regeneration of an epiphyseal growth plate or similar interfacial tissue structures. In one aspect, the disclosed technology can include a biologic material that can comprise one or more of a hydrogel carrier for growth factors and MSCs, chondrogenic and immunomodulatory cytokines, microparticles for prolonged and spatially controlled growth factor delivery; and/or porous scaffold providing mechanical support. The implanted material can be applied via various different modalities depending on the nature of the physeal injury. One modality is an injectable hydrogel and another modality is an implantable hydrogel infused scaffold.

A staple cartridge comprising a tissue thickness compensator is disclosed. The tissue thickness compensator comprises an external layer and tubular elements. The tubular elements are interconnected and positioned within the external layer. The tubular elements comprise apertures defined therein and the tubular elements are configured to collapse as pressure is applied to the tissue thickness compensator by tissue during the firing motion. The apertures enable fluids from the tissue to permeate the tissue thickness compensator.

Coated bone grafts are provided as well as methods of use thereof and methods of making. In accordance with the instant invention, methods of preparing a coated bone graft (e.g., bone allograft) are provided. In certain embodiments, the method comprises electrospraying a composition comprising a polymer and, optionally, an agent, particularly a therapeutic agent, onto the surface of the bone graft. Therapeutic agents include, without limitation: bone stimulating agents, anti-fibrotic agents, antimicrobials, anti-inflammatory agents, and pro-angiogenesis agents.

In various exemplary embodiments, the present disclosure provides organohydrogel fibers and a process for making the organohydrogel fibers. The organohydrogel fibers have a hydrophobic phase dispersed in a hydrophilic phase. The organohydrogel fibers contain at least one hydrophobic active pharmaceutical ingredient (API), and at least one hydrophilic API. The organohydrogel fibers can be formed into a non-woven or 3D printed patch and a replaceable backing can be attached to the patch to make an effective wound dressing. The wound dressing can deliver active pharmaceutical ingredients to the wound over a period of multiple days.

Magnesium-infused and menthol-infused kinesiology tape is disclosed. The tape comprises an absorbent fabric substrate with adhesive on one side of the substrate to be applied to a person's skin and includes magnesium salt and menthol for promoting pain relief while the tape adheres to the person's skin.

The invention relates to a porous osteoinductive calcium phosphate material having an average grain size in a range of 0.1-1.50 μm, having a porosity consisting essentially only of micropores in a size range of 0.1-1.50 μm, and having a surface area percentage of micropores in a range of 10-40%.

Disclosed here is a method of alleviating negative effects of cochlear implant surgery in a subject in need thereof comprising administering effective amounts of 2,4-disulfonyl α-phenyl tertiary butyl nitrone (2,4-DSPBN) or a pharmaceutically acceptable salt thereof and N-acetylcysteine (NAC) or a pharmaceutically acceptable salt thereof to a subject prior to, during, and/or after undergoing cochlear implant surgery.

A drug-releasing polymer composition is disclosed. It may include a major component, which may be ethylene vinyl acetate, and may further include at least one or two release-modifying materials, and may further include at least one or two drugs. The release-modifying materials may be polyethylene glycol and polycaprolactone. The drugs may be minocycline and rifampin. There may be an interaction such that in the presence of two different release-modifying materials, drug release may be greater than with either release-modifying material alone. There may be an interaction such that in the presence of two drugs, drug release may be greater than with either drug alone, and antibacterial performance may be enhanced. Release durations as long as two months are possible. In addition, the composition can be provided on a medical device that is configured for implanting in body tissue for an extended time period.

Antimicrobial and antithrombogenic polymer or polymeric blend, compounds, coatings, and materials containing the same, as well as articles made with, or coated with the same, and methods of making the same exhibiting improved antimicrobial properties and reduced platelet adhesion. Embodiments include polymers with antimicrobial and antithrombogenic groups bound to a single polymer backbone, an antimicrobial polymer blended with an antithrombogenic polymer, and medical devices coated with the antimicrobial and antithrombogenic polymer or polymeric blend.

Methods are disclosed for the reduction or elimination of bacterial biofilms on biological and non-biological surfaces, as well as methods for the treatment of wounds, skin lesions, mucous membrane lesions, and other biological surfaces infected or contaminated with bacterial biofilms using compositions comprising a synergistic combination of thermolysin and at least one aminoglycoside antibacterial agent.